Cidara Therapeutics logo

Cidara Therapeutics Share Price Today

(NASDAQ: CDTX)

Cidara Therapeutics share price is $23.5 & ₹2,043.77 as on 6 Mar 2025, 2.30 'hrs' IST

$23.5

0.34

(1.47%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Cidara Therapeutics share price in Dollar and Rupees. Guide to invest in Cidara Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Cidara Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Cidara Therapeutics share price movements

  • Today's Low: $22.62
    Today's High: $23.64

    Day's Volatility :4.29%

  • 52 Weeks Low: $10.00
    52 Weeks High: $28.42

    52 Weeks Volatility :64.8%

Cidara Therapeutics (CDTX) Returns

PeriodCidara Therapeutics IncIndex (Russel 2000)
3 Months
16.21%
0.0%
6 Months
100.52%
0.0%
1 Year
65.59%
0.0%
3 Years
73.54%
-11.6%

Cidara Therapeutics (CDTX) Key Statistics

in dollars & INR

Previous Close
$23.16
Open
$22.96
Today's High
$23.635
Today's Low
$22.62
Market Capitalization
$252.3M
Today's Volume
$21.0K
52 Week High
$28.42
52 Week Low
$10.004
Revenue TTM
$44.7M
EBITDA
$-43.0M
Earnings Per Share (EPS)
$-23.9
Profit Margin
-270.38%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-200.46%

How to invest in Cidara Therapeutics Stock (CDTX) from India?

It is very easy for Indian residents to invest directly in Cidara Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Cidara Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Cidara Therapeutics or CDTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Cidara Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Cidara Therapeutics shares which would translate to 0.037 fractional shares of Cidara Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Cidara Therapeutics, in just a few clicks!

Returns in Cidara Therapeutics (CDTX) for Indian investors in Rupees

The Cidara Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Cidara Therapeutics investment value today

Current value as on today

₹1,72,940

Returns

₹72,940

(+72.94%)

Returns from Cidara Therapeutics Stock

₹67,977 (+67.98%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Cidara Therapeutics (CDTX)

-29%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Cidara Therapeutics Stock from India on INDmoney has decreased by -29% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Cidara Therapeutics

  • Bvf Inc

    9.98%

  • RA Capital Management, LLC

    9.98%

  • TCG Crossover Management, LLC

    9.19%

  • VR Adviser, LLC

    7.00%

  • Bain Capital Life Sciences Investors, LLC

    6.42%

  • Vivo Capital, LLC

    6.13%

Analyst Recommendation on Cidara Therapeutics

Buy

    90%Buy

    10%Hold

    0%Sell

Based on 10 Wall street analysts offering stock ratings for Cidara Therapeutics(by analysts ranked 0 to 5 stars)

Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Cidara Therapeutics Stock (CDTX)

What analysts predicted

Upside of 34.04%

Target:

$31.50

Current:

$23.50

Insights on Cidara Therapeutics Stock (Ticker Symbol: CDTX)

  • Price Movement

    In the last 7 days, CDTX stock has moved up by 4.7%
  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 17.58M → 302.0K (in $), with an average decrease of 74.2% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -89.41M → -15.53M (in $), with an average increase of 475.5% per quarter

Cidara Therapeutics Technicals Summary

Sell

Neutral

Buy

Cidara Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Cidara Therapeutics (CDTX) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cidara Therapeutics Inc logo
15.57%
100.52%
65.59%
73.54%
-56.3%
Regeneron Pharmaceuticals, Inc. logo
1.3%
-41.29%
-30.51%
9.2%
42.38%
Beone Medicines Ltd logo
15.19%
34.31%
61.3%
43.16%
68.1%
Vertex Pharmaceuticals Incorporated logo
3.37%
3.77%
18.06%
106.43%
121.36%
Alnylam Pharmaceuticals, Inc. logo
-11.52%
-3.4%
62.32%
49.04%
120.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cidara Therapeutics Inc logo
NA
NA
0.0
-22.93
-2.0
-0.24
NA
16.41
Regeneron Pharmaceuticals, Inc. logo
17.85
17.85
1.03
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.33
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cidara Therapeutics Inc logo
Buy
$252.3M
-56.3%
NA
-270.38%
Regeneron Pharmaceuticals, Inc. logo
Buy
$74.9B
42.38%
17.85
31.07%
Beone Medicines Ltd logo
NA
$28.5B
68.1%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.1B
121.36%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.5B
120.93%
NA
-12.37%

About Cidara Therapeutics

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Organization
Cidara Therapeutics
Employees
69
CEO
Dr. Jeffrey L. Stein Ph.D.
Industry
Health Technology

Management People of Cidara Therapeutics

NameTitle
Dr. Jeffrey L. Stein Ph.D.
President, CEO & Executive Director
Mr. Shane M. Ward J.D.
COO & Corporate Secretary
Dr. Kevin M. Forrest Ph.D.
Founder & Chief Strategy Officer
Mr. Frank L. Karbe M.B.A.
Chief Financial Officer
Dr. Preetam Shah M.B.A., Ph.D.
Principal Accounting Officer
Ms. Allison Lewis CCP, SPHR
Senior Vice President of People & Culture
Dr. Leslie Tari Ph.D.
Chief Scientific Officer
Dr. Nicole Davarpanah J.D., M.D.
Interim Chief Medical Officer and Senior VP of Translational Research & Development
Mr. Jim Beitel M.B.A.
Chief Business Officer

Important FAQs about investing in CDTX Stock from India :

What is Cidara Therapeutics share price today?

Cidara Therapeutics share price today stands at $23.50, Open: $22.96 ; Previous Close: $23.16 ; High: $23.64 ; Low: $22.62 ; 52 Week High: $28.42 ; 52 Week Low: $10.00.

The stock opens at $22.96, after a previous close of $23.16. The stock reached a daily high of $23.64 and a low of $22.62, with a 52-week high of $28.42 and a 52-week low of $10.00.

Can Indians buy Cidara Therapeutics shares?

Yes, Indians can invest in the Cidara Therapeutics (CDTX) from India.

With INDmoney, you can buy Cidara Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Cidara Therapeutics at zero transaction cost.

How can I buy Cidara Therapeutics shares from India?

It is very easy to buy Cidara Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Cidara Therapeutics (CDTX) be purchased?

Yes, you can buy fractional shares of Cidara Therapeutics with INDmoney app.

What are the documents required to start investing in Cidara Therapeutics stocks?

To start investing in Cidara Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Cidara Therapeutics Stock (CDTX)?

Today’s highest price of Cidara Therapeutics (CDTX) is $23.64.

Today’s lowest price of Cidara Therapeutics (CDTX) is $22.62.

What is today's market capitalisation of Cidara Therapeutics?

Today's market capitalisation of Cidara Therapeutics CDTX is 252.3M

What is the 52 Week High and Low Range of Cidara Therapeutics Stock (CDTX)?

  • 52 Week High

    $28.42

  • 52 Week Low

    $10.00

What are the historical returns of Cidara Therapeutics (CDTX)?

  • 1 Month Returns

    15.57%

  • 3 Months Returns

    100.52%

  • 1 Year Returns

    65.59%

  • 5 Years Returns

    -56.3%

Who is the Chief Executive Officer (CEO) of Cidara Therapeutics ?

Dr. Jeffrey L. Stein Ph.D. is the current Chief Executive Officer (CEO) of Cidara Therapeutics.